[The use of aminoglutethimide in the treatment of metastatic breast cancer].
It has been demonstrated that AG inhibits the peripheric conversion of androstenedione into estrogens and produces an adrenal suppression, equivalent to surgical adrenalectomy. As breast cancer is responsive to hormonal therapy, AG has been used in the treatment of metastatic breast cancer. Since 1984, at I Clinica Ostetrica e Ginecologica of University of Torino, 48 patients with advanced breast cancer, previously treated with chemotherapy and hormonotherapy, have been given AG 1 g/day and hydrocortisone 40 mg/day. Six patients (12%) obtained CR, nine (19%) a PR, eleven (23%) a SD, twenty two (46%) a PD. The efficacy of AG has been evaluated as related to the following prognostic factors: menopausal status, hormone receptors, disease free interval, age, prior tamoxifen exposure. This study shows that bone involvement is the most responsive localization to AG. In conclusion AG is still an effective therapeutic choice in metastatic breast cancer treatment.
Bellora
M G
MG
Cattedra A di Clinica Ostetrica e Ginecologica, Università di Torino.
Ciancio
A
A
Ferrero
A
A
Bergamino
T
T
Zola
P
P
Sismondi
P
P
D000311:Adrenal Glands / Q000187:drug effects; D000367:Age Factors; D000616:Aminoglutethimide / Q000494:pharmacology / Q000627:therapeutic use*; D000735:Androstenedione / Q000037:antagonists & inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008593:Menopause; D009362:Neoplasm Metastasis / Q000517:prevention & control
D000616:Aminoglutethimide; D000735:Androstenedione
L'impiego dell'aminoglutetimide nel trattamento del carcinoma mammario metastatico.